IceCure Medical is excited to be a first-time exhibitor at the 19th Annual St. Gallen Breast Cancer Conference. The event is taking place in Vienna, Austria from March 12 – 15. Meet the IceCure team and leading experts in the field of breast cancer cryoablation at Booth 18.
About the St. Gallen Breast Cancer Conference
The focus of this year’s conference is the primary therapy of patients with early breast cancer: evidence, controversies, & consensus. The event is widely attended by medical oncologists and surgeons from across Europe, Asia, and the U.S.
IceCure’s presence at the St. Gallen Breast Cancer Conference underscores their commitment to advancing women’s health through innovation and collaboration. Through dialogue with leading oncologists and surgeons, IceCure aims to further validate the efficacy of breast cancer cryoablation in Europe.
Through the sharing of knowledge and clinical experience, IceCure aims to drive the adoption of cryoablation by breast cancer specialists. Moreover, IceCure Medical recognizes the importance of patient-centered care and strives to empower patients with more choices in their cancer care journey.
Sharing the ICE3 Clinical Trial Results & Independent Data on Breast Cancer Cryoablation with ProSense™
As a pioneer in the field of liquid nitrogen based-cryoablation, IceCure Medical has been at the forefront of developing minimally invasive cryoablation for use in breast cancer.
At the conference, IceCure will be raising awareness about the positive results of the ICE3 clinical trial on cryoablation for patients with early-stage, low-risk breast cancer. Leading experts in the field of breast cancer cryoablation will be at IceCure’s booth to share additional independent research and share their experience using our ProSense™ Cryoablation System.
Schedule a meeting with IceCure at SGBCC 2025
Want to learn more in an in-depth one-on-one meeting with IceCure? Schedule a meeting with IceCure representatives! Complete the contact form on this page.
*The breast cancer indication for the ProSense® System is currently under review by the FDA and has not yet received marketing clearance in the US. ProSense™ is cleared for the treatment of breast cancer in the EU and other select markets. Clinical indications vary by region, please contact us for additional details.